Philogen SpAMIL:PHIL +2.19%62 Interest Coverage is 1,496.56 as of Dec. 2025, which is 1933% above its 10-year median of 73.60. GuruFocus rates MIL:PHIL with a GF Score™ of 62/100 and a GF Value™ of €227.22 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 377 Biotechnology companies, Philogen SpA ranks better than 59.95% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Philogen SpA's
Operating Income
for the
six
months ended in Dec. 2025 was €273.9 Mil. Philogen SpA's Interest Expense for the
six
months ended in Dec. 2025 was €-0.2 Mil.
Philogen SpA's interest coverage for the quarter that ended in Dec. 2025 was 1,496.56.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Philogen SpA has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Philogen SpA's Interest Coverage or its related term are showing as below:
MIL:PHIL'
s Interest Coverage Range Over the Past 10 Years
Min: 2.02 Med: 73.6 Max: 697.57
Current: 697.57
MIL:PHIL's Interest Coverage is ranked better than 59.95% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs MIL:PHIL: 697.57
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Philogen SpA Interest Coverage Related Terms
Philogen SpA Interest Coverage Historical Data
* Premium members only.
The historical data trend for Philogen SpA's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
MIL:PHIL vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Philogen SpA's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Philogen SpA Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Philogen SpA's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Philogen SpA's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Philogen SpA (MIL:PHIL) has a Interest Coverage of 1,496.56 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Philogen SpA and its competitors. This is 1933% above median its historical median of 73.60. Over the past decade, Philogen SpA's Interest Coverage has ranged from 2.02 to 697.57. According to the industry distribution chart, Philogen SpA ranks #151 out of 377 companies in the Biotechnology industry, placing it in the top 40.1%.
Is Philogen SpA's Interest Coverage too high?
Philogen SpA's current Interest Coverage of 1,496.56 is 1933% above median its 10-year median of 73.60. Over the past 10 years, this metric has ranged from a low of 2.02 to a high of 697.57. The Biotechnology industry median Interest Coverage is 106.07. Philogen SpA's value of 1,496.56 is 1310.9% above this industry median. Based on the distribution chart, Philogen SpA ranks #151 out of 377 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Philogen SpA has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Philogen SpA's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Philogen SpA ranks #151 out of 377 companies for Interest Coverage. This puts Philogen SpA in the upper half of its industry. The industry median Interest Coverage is 106.07. Philogen SpA's value of 1,496.56 is 1310.9% above this benchmark. Historically, Philogen SpA's own Interest Coverage has ranged from 2.02 to 697.57 over the past decade. While the company's 10-year median is 73.60 vs. the industry median of 106.07, Philogen SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Philogen SpA's current Interest Coverage of 1,496.56 is 1310.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Philogen SpA and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Philogen SpA's current Interest Coverage is 1,496.56, which is 1933% above median its own 10-year median of 73.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Philogen SpA stock overvalued right now?
Based on GuruFocus' analysis, Philogen SpA (MIL:PHIL) is currently considered Possible Value Trap. The stock's GF Value™ is €227.22, compared to a current price of €23.30 — trading 89.7% below its estimated fair value. The current Interest Coverage is 1,496.56, which is 1933% above median its 10-year median of 73.60 and 1310.9% above the Biotechnology industry median of 106.07. Philogen SpA's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Philogen SpA (MIL:PHIL), the current Interest Coverage is 1,496.56 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Philogen SpA (MIL:PHIL) Overvalued in 2026?
Based on GuruFocus' analysis, Philogen SpA stock appears to be undervalued.
The current stock price of €23.30 is trading 89.7% below its estimated GF Value™ of €227.22.
GuruFocus considers Philogen SpA to be Possible Value Trap.
Key valuation signals for MIL:PHIL:
Interest Coverage: 1,496.56 (1933% above median its 10-year median of 73.60)
GF Value™: €227.22 vs. price of €23.30 (89.7% below fair value)
Industry Position: 1310.9% above the Biotechnology median (#151 of 377)
No single metric tells the full story. See the MIL:PHIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
62GF Score
Get the complete analysis for MIL:PHIL
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:PHIL has been successfully added to your 
